Literature DB >> 2802540

Physostigmine treatment of progressive supranuclear palsy.

I Litvan1, C Gomez, J R Atack, M Gillespie, A M Kask, M M Mouradian, T N Chase.   

Abstract

Cognitive and extrapyramidal effects of cholinomimetic therapy were evaluated in 8 patients with progressive supranuclear palsy. Each was randomized to a 10-day double-blind crossover trial of physostigmine and placebo. Physostigmine treatment was associated with marginal and inconsistent changes in long-term memory, suggesting that cholinergic therapy alone is insufficient to restore cognitive function. Motor scores remained unchanged.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2802540     DOI： 10.1002/ana.410260318

Source DB:  PubMed          Journal:  Ann Neurol        ISSN： 0364-5134            Impact factor:   10.422


  8 in total

Review 1.  Progressive supranuclear palsy (Steele-Richardson-Olszewski disease).

Authors:  H R Morris; N W Wood; A J Lees
Journal:  Postgrad Med J       Date:  1999-10       Impact factor: 2.401

2.  Treatment of frontotemporal dementia.

Authors:  Richard M Tsai; Adam L Boxer
Journal:  Curr Treat Options Neurol       Date:  2014-11       Impact factor: 3.598

Review 3.  Progressive supranuclear palsy: clinical features, pathophysiology and management.

Authors:  A Rajput; A H Rajput
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

4.  Current and future treatments in progressive supranuclear palsy.

Authors:  Irene van Balken; Irene Litvan
Journal:  Curr Treat Options Neurol       Date:  2006-05       Impact factor: 3.598

Review 5.  Clinical trials: past, current, and future for atypical Parkinsonian syndromes.

Authors:  Richard M Tsai; Adam L Boxer
Journal:  Semin Neurol       Date:  2014-06-25       Impact factor: 3.420

6.  Cerebrospinal fluid acetylcholinesterase in progressive supranuclear palsy: reduced activity relative to normal subjects and lack of inhibition by oral physostigmine.

Authors:  J R Atack; I Litvan; L J Thal; C May; S I Rapoport; T N Chase
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-09       Impact factor: 10.154

Review 7.  [Treatment for dementia in parkinsonian syndromes. Efficacy of cholinesterase inhibitors].

Authors:  I Liepelt; W Maetzler; H-P Blaicher; T Gasser; D Berg
Journal:  Nervenarzt       Date:  2008-01       Impact factor: 1.214

8.  Reduction in Volume of Nucleus Basalis of Meynert Is Specific to Parkinson's Disease and Progressive Supranuclear Palsy but Not to Multiple System Atrophy.

Authors:  Sophia Rogozinski; Martin Klietz; Gesine Respondek; Wolfgang H Oertel; Michel J Grothe; Joana B Pereira; Günter U Höglinger
Journal:  Front Aging Neurosci       Date:  2022-04-01       Impact factor: 5.702
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.